obstructive sleep apnea, FDA

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...